Sanofi inks marketing pact with Emcure for cancer drugs

Drug firm Sanofi India Ltd has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India.

As per the agreement, Sanofi will continue to own its oncology range comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec, while Emcure will market and distribute these brands through its specialty unit, Sanofi said in a filing to the Bombay Stock Exchange (BSE).

"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," Sanofi Vice-President-South Asia and Sanofi India Managing Director Shailesh Ayyangar said.

Sanofi would continue to provide strong scientific and medical support to Emcure's already well-established and fast growing oncology business, he added.

Emcure Pharmaceuticals Managing Director Satish Mehta said, "We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions."

Sanofi India Ltd shares were trading at Rs 2900 a piece on the BSE in afternoon trade (at 2:15pm), up 0.76 per cent from its previous close.